Medtronic changes investor relations leadership ahead of diabetes spinout
Ryan Weispfenning has elected to take up the challenge of creating and leading the investor relations function at the planned new diabetes company.
| Ticker |
NVCR
|
| CIK | 0001645113 |
| SIC | 3841 |
| Sector | Manufacturing |
| Industry Category | Medical Equipment |
| Industry Group | Surgical, Medical, And Dental Instruments And Supplies |
| Address | NO. 4 THE FORUM, GRENVILLE STREET, ST. HELIER, Y9, JE2 4UF |
| Website | novocure.com |
| Phone | 44 (0)15 3475 6700 |
| CEO | Asaf Danziger |
| Employees | 1,320 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Medtronic changes investor relations leadership ahead of diabetes spinoutRyan Weispfenning has elected to take up the challenge of creating and leading the investor relations function at the planned new diabetes company. Does NovoCure's (NVCR) Insider CEO Transition Strengthen Its Long-Term Oncology Strategy Or Limit Change?NovoCure announced that CEO and Director Ashley Cordova resigned effective November 30, 2025, and subsequently appointed President Frank Leonard as Chief Executive Officer of the NovoCure Group on December 1, 2025, with the company stating her departure did not involve any disagreement over operations, policies, or practices. Leonard’s promotion reflects a leadership handoff to a long-tenured internal executive who has overseen global commercial operations and development of the Tumor... Is NovoCure’s 93% Five Year Share Price Slide Now Creating an Opportunity in 2025?Wondering if NovoCure at around $11.81 is a bargain or a value trap? You are not alone, and that is exactly what we are going to unpack here. The stock has fallen a steep 60.6% year to date and is down 55.6% over the past year, with a long term slide of 93.0% over five years that has many investors reassessing both risk and upside. Recent moves in the share price have been shaped by shifting sentiment around the company’s tumor treating fields technology and its commercial traction in key... Novocure Appoints Company President Frank Leonard as Chief Executive OfficerBAAR, Switzerland, December 01, 2025--Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has resigned from the company. NovoCure (NVCR) Q3 2025 Earnings Call TranscriptAt Novocure, our mission is to extend survival in some of the most aggressive forms of cancer. Through our early years, our efforts focused mostly on the treatment of patients with glioblastoma. Now with one launch ongoing and 2 additional launches planned for next year, the scope of our mission has expanded to reach more patients who can benefit from Tumor Treating Fields in multiple solid tumor cancers. |